ANSWER: D

Rationale:

The two principal AVP receptor subtypes are coupled to entirely distinct G proteins and activate fundamentally different intracellular signaling cascades. V1a receptors are expressed on vascular smooth muscle and hepatocytes and couple to Gq proteins; Gq activates phospholipase C (PLC), which cleaves phosphatidylinositol 4,5-bisphosphate into IP3 (inositol trisphosphate) and DAG (diacylglycerol); IP3 triggers intracellular calcium release from the endoplasmic reticulum, and the resulting cytosolic calcium rise activates myosin light chain kinase, producing vascular smooth muscle contraction and systemic vasoconstriction. V2 receptors are expressed on renal collecting duct principal cells and couple to Gs proteins; Gs activates adenylyl cyclase, elevating intracellular cAMP, which activates PKA (protein kinase A), which phosphorylates AQP2-containing vesicles and drives their insertion into the apical membrane — producing the antidiuretic response. This receptor-to-G-protein pairing determines the clinical consequences of selective versus non-selective vaptan therapy: tolvaptan's V2 selectivity produces aquaresis without hemodynamic effects, while conivaptan's dual V1a/V2 blockade produces both aquaresis and loss of V1a-mediated vasomotor tone (hypotension).

• Option A: Option A is incorrect: the G protein assignments are reversed; V1a couples to Gq (not Gs) and V2 couples to Gs (not Gq).
• Option B: Option B is incorrect: V1a receptors do not couple to Gi protein; Gi-coupled receptor activation inhibits adenylyl cyclase and is not the mechanism of AVP-mediated vasoconstriction; the V1a pathway is Gq/PLC/IP3/calcium.
• Option C: Option C is incorrect: V1a and V2 receptor G protein assignments are both reversed from their correct pairings; V1a is Gq-coupled and V2 is Gs-coupled, not the other way around.
• Option E: Option E is incorrect: V1a and V2 receptors couple to different G proteins — Gq and Gs respectively — and the difference in physiological effect arises from both differential tissue expression and differential G protein coupling; characterizing both as Gs-coupled is pharmacologically incorrect.

ANSWER: B

Rationale:

AVP is synthesized exclusively by magnocellular neurons located in two hypothalamic nuclei: the supraoptic nucleus (SON) and the paraventricular nucleus (PVN). These neurons produce AVP as a larger precursor (prepro-AVP) that is packaged into neurosecretory granules and transported along axonal projections that travel through the pituitary stalk to terminate in the posterior pituitary (neurohypophysis), where the processed AVP is stored until appropriate stimuli — rising plasma osmolality detected by hypothalamic osmoreceptors, or falling effective arterial blood volume and blood pressure detected by baroreceptors — trigger its release into the systemic circulation. This anatomical arrangement explains why pituitary stalk damage, posterior pituitary tumors, head trauma, or neurosurgical procedures near the hypothalamic-pituitary axis can cause central diabetes insipidus by disrupting AVP synthesis, transport, or release.

• Option A: Option A is incorrect: the adrenal medulla produces catecholamines (epinephrine and norepinephrine), not AVP; chromaffin cells are entirely distinct from the magnocellular hypothalamic neurons responsible for AVP synthesis.
• Option C: Option C is incorrect: POMC is processed in anterior pituitary corticotroph cells to yield ACTH, beta-endorphin, and melanocyte-stimulating hormone; AVP is not a POMC-derived peptide and is not synthesized in the anterior pituitary.
• Option D: Option D is incorrect: parvocellular neurons of the PVN do produce a small-cell form of AVP that enters the portal circulation to synergize with CRH in ACTH regulation, but these neurons are not the primary site of AVP synthesis for systemic antidiuresis; the arcuate nucleus and LH regulation described here are not the anatomy of the principal AVP-producing system.
• Option E: Option E is incorrect: juxtaglomerular cells of the renal afferent arteriole produce and store renin, not AVP; renal parenchymal cells have no role in AVP synthesis or storage.

ANSWER: E

Rationale:

Plasma osmolality is the primary physiological regulator of AVP secretion. Specialized osmoreceptor neurons in the hypothalamus and circumventricular organs (particularly the organum vasculosum laminae terminalis and the subfornical organ) respond to changes in extracellular tonicity. The threshold osmolality above which AVP secretion begins is approximately 280 mOsm/kg in healthy adults; below this level, osmoreceptors are quiescent, AVP secretion is suppressed, and the kidney produces maximally dilute urine (osmolality as low as 50 to 100 mOsm/kg) to excrete excess free water. Above 280 mOsm/kg, AVP is released in a graded, proportional fashion — plasma AVP rises approximately 1 pg/mL for each 1 mOsm/kg rise in plasma osmolality — and the resulting V2 receptor activation drives AQP2 insertion and progressively concentrated urine. Understanding this threshold is essential for interpreting SIADH: in SIADH, AVP release continues autonomously below the osmotic threshold that should suppress it, explaining the combination of low plasma osmolality and inappropriately concentrated urine.

• Option A: Option A is incorrect: the osmotic threshold is approximately 280 mOsm/kg, not 310; at 310 mOsm/kg plasma osmolality is significantly hyperosmolar and AVP would already be maximally elevated; the threshold does not shift upward with volume depletion — rather, volume depletion activates a separate, non-osmotic (hemodynamic) AVP release pathway.
• Option B: Option B is incorrect: the threshold is approximately 280 mOsm/kg, not 260; below 280 mOsm/kg AVP is suppressed under normal conditions, but hemodynamic stimuli can override this suppression and maintain AVP release despite low osmolality.
• Option C: Option C is incorrect: AVP secretion is not primarily regulated by plasma potassium concentration; it is regulated by plasma osmolality (primary) and hemodynamic stimuli (secondary); potassium plays no established role in AVP regulation.
• Option D: Option D is incorrect: the threshold is approximately 280 mOsm/kg, not 295; more importantly, volume depletion and hemodynamic compromise can and do maintain AVP secretion even when osmolality is below the osmotic threshold — the non-osmotic hemodynamic pathway operates independently of the osmotic one.

ANSWER: A

Rationale:

AQP2 is the principal AVP-regulated aquaporin and is the rate-limiting determinant of water reabsorption in the collecting duct. Under basal conditions without AVP signaling, AQP2 resides in intracellular vesicles within collecting duct principal cells and the apical membrane is relatively impermeable to water. When AVP binds V2 receptors and activates the Gs/cAMP/PKA cascade, PKA phosphorylates serine-256 on the cytoplasmic tail of AQP2, which triggers vesicle trafficking and fusion with the apical (luminal) plasma membrane, inserting functional water channels at the site where water must enter the cell from the hypotonic tubular lumen. The hyperosmolar medullary interstitium provides the osmotic driving force; once AQP2 channels are open in the apical membrane, water moves passively from the lumen into the cell, and exits through constitutively expressed basolateral AQP3 and AQP4 channels into the interstitium. This precisely localized insertion is what tolvaptan's V2 receptor blockade prevents — not AQP2 synthesis, but its regulated membrane trafficking.

• Option B: Option B is incorrect: AQP1 is constitutively expressed on both apical and basolateral membranes of proximal tubule cells and the descending thin limb; it is not regulated by AVP or PKA, and its expression does not change in response to V2 receptor signaling.
• Option C: Option C is incorrect: the thick ascending limb is a water-impermeable segment — no aquaporins are expressed here and AVP does not drive water reabsorption in this nephron segment; the thick ascending limb reabsorbs sodium, potassium, and chloride via NKCC2 without water, which is what generates the medullary hypertonicity that drives collecting duct water reabsorption.
• Option D: Option D is incorrect: AQP3 is constitutively expressed on the basolateral membrane of collecting duct principal cells (not the apical membrane) and provides the exit pathway for water reabsorbed through apical AQP2; it is not the AVP-regulated isoform, and it is not inserted de novo by PKA activation.
• Option E: Option E is incorrect: AQP2 is inserted into the apical membrane, not the basolateral membrane; the apical insertion is the regulated, rate-limiting step; basolateral water exit is provided by the constitutive AQP3 and AQP4 channels.

ANSWER: C

Rationale:

The urine sodium criterion for SIADH is above 40 mEq/L on a normal sodium intake, and this finding is one of the five required diagnostic criteria codified by Ellison and Berl and refined by the 2013 Verbalis consensus panel. The physiological principle it reflects is the euvolemic state of SIADH: because inappropriate AVP secretion causes free-water retention rather than sodium retention, total body sodium is not depleted and intravascular volume is maintained near normal. Volume receptors — including atrial low-pressure stretch receptors and carotid baroreceptors — do not perceive a volume deficit and therefore do not activate the sodium-conserving pathways (aldosterone-mediated ENaC upregulation, sympathetic-driven proximal tubular sodium reabsorption) that would otherwise drive urine sodium below 20 mEq/L. The kidney continues to excrete sodium at a rate reflecting dietary intake, producing urine sodium above 40 mEq/L despite the low serum sodium. This is the critical discriminator from hypovolemic hyponatremia: in volume depletion, urine sodium falls below 20 mEq/L as the kidney maximally conserves sodium to restore intravascular volume — a finding that should immediately redirect management toward isotonic saline rather than vaptan therapy.

• Option A: Option A is incorrect: urine sodium below 20 mEq/L is the pattern of hypovolemic hyponatremia, not SIADH; in SIADH, volume sensors perceive euvolemia and do not activate sodium conservation, so urine sodium remains elevated.
• Option B: Option B is incorrect: the kidney does not retain sodium to correct hyponatremia — hyponatremia is a water excess disorder in SIADH, not a sodium deficit, and the kidney responds to the perceived euvolemia by continuing to excrete sodium normally.
• Option D: Option D is incorrect: there is no established "indeterminate range" of 20 to 40 mEq/L as a SIADH criterion; the diagnostic threshold is above 40 mEq/L, and values in the 20 to 40 range may reflect dietary sodium restriction or early hypovolemia rather than SIADH.
• Option E: Option E is incorrect: the criterion is urine sodium above 40 mEq/L, not above 60 mEq/L specifically; values between 40 and 60 mEq/L are fully consistent with SIADH and do not require reclassification as early volume depletion.

ANSWER: D

Rationale:

Tolvaptan is a highly selective, competitive V2 receptor antagonist with no clinically meaningful V1a receptor activity at approved therapeutic doses. By blocking V2 receptors on renal collecting duct principal cells, it prevents AVP-driven AQP2 insertion and produces electrolyte-free water excretion (aquaresis), raising serum sodium without affecting vasomotor tone. Conivaptan (Vaprisol) is pharmacologically distinct: it is a non-selective antagonist that blocks both V1a and V2 receptors. Its V2 blockade produces aquaresis, while its V1a blockade removes AVP-mediated vasoconstriction from vascular smooth muscle, introducing a hemodynamic risk — hypotension — that is not shared by tolvaptan. This difference in receptor selectivity is clinically consequential: tolvaptan can be used in outpatient settings and does not require hemodynamic monitoring for its vasomotor effects, while conivaptan requires inpatient monitoring and is approved only for a maximum of 4 days given its hypotension risk.

• Option A: Option A is incorrect: the receptor selectivity assignments are reversed; tolvaptan is the selective V2 agent and conivaptan is the non-selective dual V1a/V2 agent.
• Option B: Option B is incorrect: tolvaptan's clinical effect is V2-mediated aquaresis, not V1a-mediated vasopressor reduction; a selective V1a antagonist would produce vasodilation without aquaresis, which is not tolvaptan's mechanism.
• Option C: Option C is incorrect: tolvaptan and conivaptan do not have identical receptor selectivity profiles; tolvaptan is V2-selective while conivaptan is a dual V1a/V2 antagonist — this is a pharmacologically fundamental distinction, not merely a route difference.
• Option E: Option E is incorrect: tolvaptan is a competitive antagonist, not a partial agonist; it does not produce submaximal antidiuresis by partial agonism — it blocks the receptor and prevents AVP from signaling; conivaptan is also an antagonist, not a full agonist.

ANSWER: B

Rationale:

Desmopressin (1-desamino-8-D-arginine vasopressin; DDAVP) contains two engineered structural modifications relative to native AVP. The modification at position 1 is deamination of the cysteine residue — removal of the free amino group at the N-terminus of the nonapeptide ring. This free amino group is the primary site of attack by aminopeptidase enzymes in plasma and tissues, which cleave native AVP at this position and account for its very short plasma half-life of approximately 5 to 15 minutes. By eliminating the aminopeptidase cleavage site through deamination, desmopressin resists this enzymatic degradation and has a half-life of several hours — making it suitable for subcutaneous injection (1 to 4 mcg once or twice daily), intranasal spray (10 to 40 mcg once or twice daily), and oral tablet (0.1 to 0.4 mg two to three times daily) without the continuous infusion required for native vasopressin. The second modification — D-arginine at position 8 — is a separate change responsible for V1a selectivity loss. These two modifications serve distinct pharmacological purposes: position 1 deamination extends half-life; position 8 D-arginine eliminates vasopressor activity.

• Option A: Option A is incorrect: the D-arginine for L-arginine substitution is the modification at position 8, not position 1; position 1 is the deamination site responsible for half-life prolongation.
• Option C: Option C is incorrect: desmopressin does not contain a PEG moiety; it is a small synthetic peptide, not a PEGylated biologic; the half-life extension is achieved through aminopeptidase resistance from deamination, not from steric protection by a polymer chain.
• Option D: Option D is incorrect: the modification at position 1 is deamination of cysteine, not methylation of tyrosine; tyrosine is at position 2 in AVP and is not the site of the clinically relevant modification in desmopressin.
• Option E: Option E is incorrect: the modification is deamination of cysteine (removal of the amino group), not substitution of D-cysteine for L-cysteine; stereoisomer substitution at position 1 is not the mechanism of either half-life prolongation or receptor selectivity in desmopressin.

ANSWER: A

Rationale:

Tolvaptan is a highly lipophilic molecule that undergoes extensive CYP3A4-mediated oxidative metabolism in the liver and intestinal wall, with the resulting metabolites eliminated predominantly via fecal excretion. Its oral bioavailability is approximately 56%, reflecting both intestinal absorption and first-pass CYP3A4 metabolism. Because the renal clearance of unchanged tolvaptan is negligible relative to total hepatic-fecal clearance, renal impairment does not meaningfully alter tolvaptan pharmacokinetics and dose adjustment for reduced GFR is not required. The clinically important pharmacokinetic interaction is with CYP3A4 modulators: strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, clarithromycin, or voriconazole) substantially reduce hepatic clearance and raise tolvaptan plasma concentrations, intensifying aquaresis and increasing the risk of sodium overcorrection; strong CYP3A4 inducers (such as rifampin) accelerate clearance and reduce efficacy.

• Option B: Option B is incorrect: tolvaptan is not renally excreted as unchanged parent drug; its fecal-predominant elimination means that GFR reduction does not cause drug accumulation and renal dose adjustment is not indicated in the prescribing information.
• Option C: Option C is incorrect: tolvaptan's primary metabolic pathway is CYP3A4-mediated oxidation, not UGT1A4-mediated glucuronidation; the primary elimination route is hepatic/fecal, not equally shared between renal and hepatic pathways.
• Option D: Option D is incorrect: tolvaptan's primary metabolic enzyme is CYP3A4, not CYP2D6; oral bioavailability is approximately 56% — not low and highly variable — and CYP2D6 metabolizer status is not clinically relevant to tolvaptan pharmacokinetics.
• Option E: Option E is incorrect: tolvaptan does not undergo biliary excretion of unchanged drug without prior metabolism; it is extensively metabolized by CYP3A4 before excretion, and biliary obstruction is not a recognized cause of tolvaptan accumulation requiring dose adjustment.

ANSWER: E

Rationale:

Conivaptan (Vaprisol) is the only FDA-approved intravenous vaptan and has no approved oral formulation. Its approved dosing regimen consists of a 20 mg loading dose infused over 30 minutes, followed by a continuous infusion of 20 mg over 24 hours, with the option to increase to 40 mg per 24 hours if the serum sodium response is inadequate at 24 hours. The maximum approved treatment duration is 4 days, a restriction that reflects two converging considerations: the inpatient-only context for which it is designed, and the hemodynamic monitoring requirements imposed by its V1a receptor blockade — which can cause hypotension through loss of AVP-mediated vasomotor tone, particularly in patients with elevated baseline AVP levels and borderline blood pressure. Conivaptan is approved for both euvolemic and hypervolemic hyponatremia in hospitalized patients who cannot take oral medications.

• Option A: Option A is incorrect: conivaptan does not have an approved oral formulation; there is no oral tablet available for outpatient use, and the maximum inpatient duration is 4 days, not 14.
• Option B: Option B is incorrect: conivaptan is administered intravenously, not as an oral tablet; the 30-day duration applies to tolvaptan (Samsca) for hyponatremia, not to conivaptan.
• Option C: Option C is incorrect: conivaptan is not administered subcutaneously; it is an intravenous infusion; subcutaneous administration is not an approved route and is not described in the prescribing information.
• Option D: Option D is incorrect: the maximum approved duration is 4 days, not 14 days; V1a receptor downregulation is not the pharmacological basis for the 4-day limit — the limit reflects inpatient monitoring requirements and the hemodynamic risk of V1a blockade, not a receptor regulation phenomenon.

ANSWER: C

Rationale:

The pons is the structure most classically and disproportionately affected in osmotic demyelination syndrome — to the degree that the condition was originally named central pontine myelinolysis before it was recognized that extrapontine sites (basal ganglia, thalamus, cerebellum) can also be involved. Two anatomical features of the pons explain its exceptional vulnerability. First, the arterial supply to the central pons is provided by a compact plexus of short perforating arteries arising from the basilar artery that lack the extensive anastomotic connections present in the cortex and other brain regions; this relative vascular isolation limits the ability to redistribute perfusion in response to local osmotic stress. Second, the pons has an exceptionally high myelin density — it contains a large concentration of tightly packed myelinated fiber tracts with a relatively low ratio of neurons to myelin-producing oligodendrocytes — and the demyelinating injury of ODS concentrates in myelin-rich tissue. The clinical consequences reflect the anatomy: descending corticospinal tracts produce quadriparesis, corticobulbar fibers produce dysarthria and dysphagia, and in severe cases complete pontine demyelination produces the locked-in state.

• Option A: Option A is incorrect: the cerebral cortex is not the primary site of ODS; while cortical neurons are metabolically active, the demyelinating injury of ODS concentrates in white matter tracts, and cortical involvement is not the defining or most characteristic feature.
• Option B: Option B is incorrect: the cerebellum is not the most vulnerable structure in ODS; Purkinje cell axon myelin thickness is not the basis of ODS vulnerability; cerebellar features may occur in extrapontine myelinolysis but the pons is the defining site.
• Option D: Option D is incorrect: AQP4-mediated water flux in hippocampal astrocytes is not the established mechanism of ODS vulnerability; the hippocampus is not the most vulnerable structure; ODS does not characteristically produce an amnestic syndrome.
• Option E: Option E is incorrect: thalamic neurons do not have high V2 receptor expression; V2 receptors mediate renal antidiuresis and are not expressed at clinically relevant levels in central neurons; cAMP disruption in thalamic neurons is not the mechanism of ODS.

ANSWER: D

Rationale:

Von Willebrand disease is classified by the quantitative and qualitative nature of the vWF defect. Type 1 vWD is quantitatively reduced but qualitatively normal vWF — the most common form — in which Weibel-Palade bodies contain structurally normal vWF at reduced quantities; desmopressin produces a two- to fivefold rise from this reduced baseline and is typically adequate for minor procedural hemostasis. Type 3 vWD represents the severe end of the quantitative spectrum: near-total absence of vWF due to severely reduced or absent vWF synthesis from both alleles. Weibel-Palade bodies either contain negligible vWF or are substantially depleted; when desmopressin activates V2 receptors and triggers PKA-mediated exocytosis normally, the granules have essentially nothing to release — the cAMP/PKA mechanism is intact, but the hemostatic cargo is absent. The resulting rise in plasma vWF and factor VIII is clinically insignificant and insufficient for any hemostatic coverage. These patients require exogenous vWF concentrate (with or without factor VIII) for all procedures.

• Option A: Option A is incorrect: the description of a gain-of-function mutation causing spontaneous platelet GPIb binding and thrombocytopenia upon desmopressin use is the pharmacology of type 2B vWD — not type 3; type 3 is a quantitative deficiency, not a qualitative gain-of-function defect.
• Option B: Option B is incorrect: type 3 vWD involves near-total absence of vWF (quantitative), not qualitatively dysfunctional vWF; the description of dysfunctional vWF that cannot bind collagen is closer to type 2M or type 2A qualitative subtypes.
• Option C: Option C is incorrect: endothelial V2 receptors are not impaired in type 3 vWD; the V2 receptor gene (AVPR2) is not the site of the type 3 vWD mutation, which resides in the vWF gene (VWF); the signaling cascade is fully intact.
• Option E: Option E is incorrect: desmopressin's hemostatic effect is mediated through V2 receptors, not V1a receptors, on endothelial cells; V1a receptors are not the endothelial trigger for Weibel-Palade body exocytosis; this option inverts the receptor pharmacology.

ANSWER: B

Rationale:

Tolvaptan marketed as Samsca for the hyponatremia indication is approved for inpatient use not exceeding 30 days. Both the inpatient initiation requirement and the 30-day duration limit are regulatory conditions in the FDA-approved prescribing information. Inpatient initiation is required because the magnitude and rate of aquaresis produced by tolvaptan are variable and patient-dependent, creating a risk that serum sodium may rise too rapidly in some patients; the mandatory monitoring protocol — sodium checks at 6, 12, and 24 hours after the first dose, and at least twice daily thereafter — can only be reliably implemented in a monitored inpatient setting. The 30-day limit reflects the clinical reality that tolvaptan corrects hyponatremia only while administered (serum sodium returns to baseline within 7 days of discontinuation, as shown in the SALT trials), and ongoing use beyond 30 days without resolution of the underlying SIADH cause would represent indefinite pharmacological management of a condition whose root cause should be addressed. Importantly, the 30-day inpatient limit and the hepatotoxicity black box warning are each distinct to their respective indications — the hepatotoxicity warning applies specifically to the ADPKD indication at higher doses, not to the 30-day inpatient Samsca hyponatremia use.

• Option A: Option A is incorrect: tolvaptan for hyponatremia is not approved for indefinite outpatient use; the 30-day inpatient limit and the requirement for initiation in a monitored setting are formal prescribing information requirements.
• Option C: Option C is incorrect: the approved maximum duration is 30 days, not 7 days; there is no requirement to transition to fluid restriction after 7 days as a fixed protocol step.
• Option D: Option D is incorrect: the 30-day restriction applies to the hyponatremia indication (Samsca), not the ADPKD indication (Jynarque); Jynarque for ADPKD is taken long-term (years) with monthly liver monitoring, not limited to 30 days.
• Option E: Option E is incorrect: tolvaptan for hyponatremia is not approved for outpatient use, and the duration limit is 30 days, not 90; there is no approved washout and restart protocol.

ANSWER: A

Rationale:

The therapeutic rationale for V2 receptor antagonism in ADPKD exploits the central role of cyclic AMP (cAMP) in cyst pathology. In polycystic kidney disease, tubular epithelial cells harboring PKD1 or PKD2 mutations (encoding polycystin-1 and polycystin-2) have dysregulated intracellular calcium signaling that sensitizes them to the proliferative and secretory effects of cAMP. When AVP binds V2 receptors on collecting duct-derived cyst-lining cells, the standard Gs/adenylyl cyclase pathway raises intracellular cAMP, and in the PKD cellular context this elevated cAMP drives two distinct cyst-expanding processes: activation of B-Raf/MEK/ERK kinase cascades that promote cyst epithelial cell proliferation, and activation of apical CFTR (cystic fibrosis transmembrane conductance regulator)-mediated chloride secretion that drives osmotic fluid entry into the cyst lumen. By competitively blocking V2 receptors, tolvaptan reduces AVP-driven cAMP accumulation in cyst epithelial cells and attenuates both the proliferative and secretory components — a pharmacological rationale arising from the same V2/cAMP mechanism as the antidiuretic effect but expressed in a pathologically different cell population.

• Option B: Option B is incorrect: tolvaptan is a selective V2 antagonist with no meaningful V1a activity; the ADPKD mechanism is entirely V2/cAMP-dependent, not V1a/calcium-dependent; V1a receptor expression on cyst epithelium is not the driver of cyst expansion in ADPKD.
• Option C: Option C is incorrect: the relationship between V2/cAMP signaling and mTOR in ADPKD is that elevated cAMP activates mTOR through Akt-independent pathways, contributing to proliferation — it does not downregulate mTOR; tolvaptan's benefit is from reducing cAMP, not from restoring mTOR activity.
• Option D: Option D is incorrect: AQP2 overexpression and osmotic fluid influx into cysts is not the established mechanism of cyst expansion in ADPKD; the primary drivers are epithelial proliferation and CFTR-mediated chloride/fluid secretion, both cAMP-driven; AQP2 regulation is not the pharmacological basis for tolvaptan's ADPKD efficacy.
• Option E: Option E is incorrect: a prostaglandin E2-driven autocrine cAMP amplification loop that operates independently of V2 receptor activation is not an established component of ADPKD cyst pathology, and this mechanism is not supported by the ADPKD pharmacology literature; tolvaptan's clinical efficacy in ADPKD trials demonstrates meaningful disease slowing that is inconsistent with an intact prostaglandin-driven bypass loop limiting its action.

ANSWER: E

Rationale:

The standard intravenous hemostatic dose of desmopressin is 0.3 mcg/kg administered by infusion over 15 to 30 minutes — the slower infusion rate compared with a bolus is used to minimize facial flushing, mild hypotension, and reflex tachycardia that can occur with more rapid administration. This dose reliably produces a two- to fivefold rise in plasma vWF antigen, vWF ristocetin cofactor activity (the functional measure of vWF-dependent platelet adhesion), and factor VIII coagulant activity within 30 to 60 minutes of completing the infusion. The hemostatic effect peaks at approximately 60 minutes post-infusion and lasts approximately 4 to 8 hours, providing a window adequate for most minor procedures. A pre-procedure test dose measuring factor VIII and vWF levels at baseline and 60 minutes post-infusion is recommended before any planned procedure to confirm an adequate individual response and guide dosing strategy, since response magnitude varies among patients even within the same vWD subtype.

• Option A: Option A is incorrect: the dose is 0.3 mcg/kg (not 0.03 mcg/kg), the magnitude of rise is two- to fivefold (not ten- to fifteenfold), the timing is 30 to 60 minutes (not 2 to 4 hours), and desmopressin is not indicated for moderate hemophilia A.
• Option B: Option B is incorrect: the dose is 0.3 mcg/kg (not 3.0 mcg/kg — which would be tenfold the standard dose); rapid 5-minute infusion is not the standard protocol; V2 receptor internalization during infusion is not the pharmacokinetic rationale for dosing rate.
• Option C: Option C is incorrect: while a pre-procedure test dose is indeed recommended, the response to 0.3 mcg/kg is not "highly unpredictable across a tenfold range" — the expected range of two- to fivefold is well-established; a test dose is recommended to confirm response but the response range is clinically predictable for appropriate candidates.
• Option D: Option D is incorrect: desmopressin is administered as a diluted infusion over 15 to 30 minutes, not as a rapid undiluted bolus; desmopressin's deamination at position 1 already provides aminopeptidase resistance, so a rapid bolus is not needed to prevent enzymatic degradation before reaching endothelial receptors.

ANSWER: C

Rationale:

In hypovolemic hyponatremia — caused by gastrointestinal losses, diuretic overuse, third-spacing, hemorrhage, or other causes of intravascular volume depletion — two simultaneous physiological responses operate in parallel. First, reduced effective arterial blood volume activates aldosterone (via the renin-angiotensin-aldosterone axis) and sympathetic-mediated proximal tubular sodium reabsorption, together driving maximal renal sodium conservation and producing urine sodium below 20 mEq/L. Second, baroreceptor-mediated non-osmotic AVP release drives free-water retention in the collecting duct, worsening the hyponatremia by adding excess water to the already sodium-depleted body. The correct treatment is isotonic saline: restoring intravascular volume removes the baroreceptor stimulus for AVP secretion, AVP levels fall, and the kidney regains its ability to dilute urine and excrete the accumulated free water — spontaneously correcting the sodium toward normal. Vaptans are absolutely contraindicated in this context because aquaresis (free-water loss) in a patient who is already volume-depleted would further reduce intravascular volume and worsen hemodynamic compromise. The urine sodium below 20 mEq/L is the single most important laboratory discriminator from SIADH (urine sodium above 40 mEq/L) and should immediately redirect management toward saline rather than vaptan therapy.

• Option A: Option A is incorrect: urine sodium above 40 mEq/L is the SIADH pattern, not hypovolemic hyponatremia; volume depletion causes AVP release but simultaneously activates maximal sodium conservation (low urine sodium), not sodium wasting.
• Option B: Option B is incorrect: urine sodium above 40 mEq/L with renal sodium wasting as the primary cause describes a different category of hyponatremia (cerebral salt wasting or mineralocorticoid deficiency), not typical hypovolemic hyponatremia from extrarenal losses; fludrocortisone is not the standard initial treatment.
• Option D: Option D is incorrect: hypertonic saline is indicated for acute symptomatic hyponatremia with neurological compromise — not for hypovolemic hyponatremia where the correct treatment is volume restoration with isotonic saline; and the assertion that volume depletion protects against ODS is incorrect — the safe correction rate ceiling applies regardless of volume status.
• Option E: Option E is incorrect: urine sodium is highly diagnostically useful in hyponatremia — it is one of the key discriminators between hypovolemic (low urine Na) and euvolemic SIADH (high urine Na) patterns; treatment is not determined by sodium severity thresholds alone but by the underlying volume status and mechanism.

ANSWER: B

Rationale:

The inability to perceive or respond to thirst is an absolute contraindication to tolvaptan explicitly stated in the FDA prescribing information and reinforced by the 2013 Verbalis expert panel. The pharmacological basis is mechanistic and straightforward: tolvaptan produces ongoing, concentration-dependent aquaresis by blocking V2 receptors on collecting duct principal cells, preventing AQP2 insertion and generating continuous free-water excretion. The only physiological mechanism that buffers this aquaresis-driven rise in plasma osmolality and serum sodium is the thirst drive — rising tonicity activates hypothalamic osmoreceptors, generates thirst, and the patient drinks free water that replaces the excreted water and moderates the rate of sodium rise. When this mechanism is absent — due to adipsic or hypodipsic conditions, altered consciousness, physical inability to access water, or institutional restriction of oral fluids — the aquaresis proceeds without buffering and serum sodium rises without limit, potentially producing fatal hypernatremia. The prescribing checklist before initiating any vaptan must include confirmation that the patient has intact thirst perception and unrestricted access to oral fluids.

• Option A: Option A is incorrect: tolvaptan is predominantly eliminated by CYP3A4-mediated hepatic metabolism with fecal excretion, not by renal clearance; reduced GFR does not cause tolvaptan accumulation and renal dose adjustment is not required; serum creatinine elevation is not an absolute contraindication.
• Option C: Option C is incorrect: concurrent loop diuretic use is not an absolute contraindication to tolvaptan; the combination requires careful electrolyte and sodium monitoring but is not prohibited, and it does not invariably produce hypernatremia within 48 hours — the two agents act through different mechanisms that can be managed concurrently with appropriate monitoring.
• Option D: Option D is incorrect: a sodium threshold of 120 mEq/L is not an absolute contraindication to vaptan initiation; the contraindication for acute symptomatic hyponatremia requiring urgent correction applies to situations where hypertonic saline is needed and rate control is critical — not to a specific sodium threshold that prohibits vaptans below that value.
• Option E: Option E is incorrect: age above 75 years is not an absolute contraindication to tolvaptan, and age-related V2 receptor downregulation causing exaggerated aquaretic responses is not a pharmacologically established phenomenon; elderly patients do require more careful monitoring given higher background risk of hyponatremia and impaired thirst sensation, but age alone is not a listed absolute contraindication.